Head-To-Head Contrast: C R Bard (BCR) and LDR (LDRH)

LDR (NASDAQ: LDRH) and C R Bard (NYSE:BCR) are both companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current recommendations and price targets for LDR and C R Bard, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LDR 0 0 0 0 N/A
C R Bard 0 7 0 0 2.00

C R Bard has a consensus target price of $310.60, indicating a potential downside of 6.23%. Given C R Bard’s higher possible upside, analysts plainly believe C R Bard is more favorable than LDR.

Insider and Institutional Ownership

79.1% of C R Bard shares are held by institutional investors. 0.8% of C R Bard shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dividends

C R Bard pays an annual dividend of $0.78 per share and has a dividend yield of 0.2%. LDR does not pay a dividend. C R Bard has raised its dividend for 46 consecutive years.

Earnings and Valuation

This table compares LDR and C R Bard’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LDR N/A N/A N/A N/A N/A
C R Bard $3.71 billion 6.50 $531.40 million N/A N/A

C R Bard has higher revenue and earnings than LDR.

Profitability

This table compares LDR and C R Bard’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LDR -18.02% -16.37% -13.65%
C R Bard 9.51% 19.39% 6.91%

Summary

C R Bard beats LDR on 9 of the 9 factors compared between the two stocks.

About LDR

LDR Holding Corporation is a medical device company. The Company focuses on designing and commercializing surgical technologies for the treatment of patients suffering from spine disorders. The Company’s primary products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, both of which are designed for applications in the cervical and lumbar spine. The Company’s VerteBRIDGE products are designed around its plating technology that enables surgeons to implant VerteBRIDGE devices with direct visualization of the disc and to affix the devices to the vertebrae from inside the spinal disc space. The Company’s Mobi non-fusion platform is underlined by Mobi-C, a cervical disc replacement device with a mobile bearing core that is designed to replicate the natural anatomical movement of the spine by facilitating independent bending and twisting similar to a healthy disc. The Company’s traditional fusion products include Easyspine, MC+, ROI, ROI-T, SpineTune and C-Plate.

About C R Bard

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive News & Ratings for LDR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LDR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply